CAMP4 Therapeutics Corporation (CAMP) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$12.87M*; Operating income -$13.38M; Depreciation and amortization $515.00K*.
- 2026-03-31: Basis Reported; EBITDA -$12.55M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$12.4M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$13.23M*; Operating income -$13.65M; Depreciation and amortization $416.00K*.
Complete source-backed ebitda history.
- Available history
- 2023-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$12.87M* | -$13.38M | $515.00K* | (m) | (m) | $129.00K* | -$12.69M* | (m) | $10.82M | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | -$12.55M | (m) | (m) | (m) | -969.94% | $0.00 | -$10.98M | (m) | $10.16M | (m) | $0.00 |
|---|
| 2025-12-31 | Reported | -$12.4M | (m) | (m) | (m) | -3564.37% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$13.23M* | -$13.65M | $416.00K* | $795.00K | -1664.78%* | $0.00* | -$11.22M* | (m) | $9.36M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$12.60M* | -$13.03M | $430.00K* | $1.50M | -841.55%* | $0.00* | -$10.34M* | (m) | $10.34M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$12.68M | (m) | (m) | (m) | -1477.74% | $279.00K | -$14.29M | (m) | $10.15M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$13.62M | (m) | (m) | (m) | -2088.34% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$13.10M* | -$13.52M | $418.00K* | $0.00 | (m) | $0.00* | -$9.69M* | (m) | $9.70M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | -$12.24M* | -$12.66M | $424.00K* | $0.00 | (m) | $163.00K* | -$13.44M* | (m) | $9.39M | (m) | $0.00 |
|---|
| 2024-03-31 | Reported | -$12.44M | (m) | (m) | (m) | (m) | $15.00K | -$11.14M | (m) | $9.74M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$13.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | (m) | -$12.34M | (m) | (m) | (m) | (m) | (m) | (m) | $9.82M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$50.92M | (m) | (m) | (m) | -1455.57% | $279.00K | -$29.55M | (m) | $38.20M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$51.39M | (m) | (m) | (m) | -7882.21% | $441.00K | -$45.56M | (m) | $38.82M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$50.2M | (m) | (m) | (m) | -14343.14% | $678.00K | -$44.16M | (m) | $40.62M | (m) | $0.00 |
|---|